MSig classification also highlights the prognostic significance of TP53, EGFR, and IDH1 mutations in the tumour‐driving C2 subtype and the therapeutic potential of targeting the classical tumour pathway in the C5 subtype. This evidence concerns the gene TP53 and neoplasm.